CNBC January 13, 2025
Key Points
– Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg.
– Eli Lilly and Novo Nordisk, which dominate the market with their obesity injections Zepbound and Wegovy, respectively, are both looking to develop next-generation versions.
– A weight loss pill would offer more convenience to patients and would be easier to manufacture.
Eli Lilly expects its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks told Bloomberg TV on Monday.
The company is set to release key late-stage trial data on the drug, orforglipron, by the middle of this year.
Eli Lilly is pushing to get the...
Today's Sponsors
Today's Sponsor